Medtronic reported a 1.94% increase in its share performance on the most recent trading day, even as the overall market experienced a downturn. Trading volume reached approximately 7.7 million shares, marking a 12% rise over its 30-day average. This relative strength underscores investor confidence in Medtronic’s portfolio of cardiac rhythm management and insulin pump devices, which collectively account for over 40% of the company’s revenue.

On January 29, 2026, China International Capital Corporation initiated coverage of Medtronic with an “Outperform” rating, citing the company’s robust R&D pipeline and expanding minimally invasive surgical offerings. CICC highlighted Medtronic’s strong balance sheet—featuring a market capitalization of about USD 129.5 billion—and projected double-digit earnings growth in its neuromodulation and respiratory care units over the next two fiscal years.

In its fourth-quarter 2025 filing, the Eaton Vance Worldwide Health Sciences Fund disclosed a 49.25% reduction in its position in a major diabetes-care peer, reallocating capital toward leading medical-device innovators. The fund’s shift reflects a thematic focus on aging demographics and the adoption of advanced implantable therapies—trends that underpin its conviction in Medtronic’s long-term growth trajectory.